As Juvena continues to welcome a tremendously talented team, we wanted to thank FierceBiotech, Endpoints News, STAT, Longevity.Technology, BioWorld, and BioCentury for highlighting Juvena Therapeutics’ expanded leadership team last week. Juvena is thrilled to have Neil Berkley as Chief corporate development officer, Gayathri Swaminath, Ph.D, MBA as SVP of discovery, Mo Tabrizi PhD, RPh as VP of preclinical and non-clinical development, and Edward Moler, PhD as VP of data science. Juvena is looking forward to what’s ahead!
BioWorld Features Dr. Yousef’s and Dr. O’Connell’s founding story, showcasing Juvena’s proteomics platform to tackle chronic and age-related diseases by mining hESC-secreted proteins
Juvena’s Head of Data Science, Dr. Eddie Moler interviewed about his experiences in data science and AI applied to diagnostics and drug discovery and shares why he is excited about Juvena
Longevity industry leaders including Juvena CEO Hanadie Yousef, PhD, will discuss key areas of innovation advancing human healthspan and longevity at the Second Annual Longevity Summit
Juvena’s lead drug discovery Scientist, Dr. Thach Mai, gave an excellent lecture, “Mapping Secreted Proteins to Unmet Medical Needs” to graduate students at Maastricht Centre for Systems Biology (MaCSBio). Dr. Mai outlined Juvena’s use of machine learning and computational tools to unravel the therapeutic potential of stem cell-secreted human proteins
